Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GNPX vs NVS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NVS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

NVS Overall Winner 6-Pillar Tally: GNPX 0 – 5 NVS (1 Tie) Matrix Metrics: GNPX 1 – 9 NVS

As of Nov 20, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas NVS carries 37.0/100 (SELL) at $150.47 (15.2x Forward P/E, 34.0% operating margin).

  • Composite vs. Pillar Nuance: While GNPX currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. NVS 37.0/100 SELL), NVS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 0.0% operating margin) and revenue trajectory (+4.7% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile NVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GNPX vs NVS
GNPX NASDAQ
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48
NVS NYSE Head-to-Head Winner
Novartis AG
Pharmaceutical Preparations
$150.47
-0.5% 1D
Market Cap $285.6B
TTM Revenue $40.5B
Forward P/E 15.2x
Beta / 30D Vol 0.32β · 28% Vol
Unified Composite Score
37.0 / 100 SELL
Tech 20.0 Fund 34.0 Flow 50.0 Mom 36.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 39
RSI-14: 38.7 · SMA20: $159.16 · SMA50: $150.46

6-Pillar Scorecard Institutional Category Breakdown (GNPX 0 – 5 NVS)

Columns: Metric · GNPX · NVS
1. Valuation Multiples NVS
Forward P/E N/M 15.2x
Trailing P/E N/M 28.9x
PEG Ratio N/M 3.69x
EV / Revenue N/M 7.1x
2. Growth & Scale NVS
Revenue Growth (YoY) +0.0% +4.7%
Earnings Growth (YoY) +0.0% -68.8%
TTM Revenue (USD) N/A $40.5B
Market Cap $2.2M $285.6B
3. Profitability & Quality NVS
Gross Margin N/A 75.2%
Operating Margin 0.0% 34.0%
Net Profit Margin 0.0% 17.5%
Return on Equity (ROE) -233.7% 24.3%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) N/A $17.0B EBITDA
Cash Flow Margin N/A 42.0% EBITDA Mgn
Net Cash / Leverage $11.26 Book/Sh · -233.7% ROE $19.71 Book/Sh · 24.3% ROE
Dividend Yield None (0.00%) 3.13%
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 16.9% (6th %ile)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity N/A 41.2% of Rev ($16.7B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GNPX (1) vs NVS (9)
Institutional Metric GNPX NVS Criterion Row Edge
Market Capitalization
Scale
$2.2M $285.6B Larger Scale NVS
Trailing P/E Ratio
Valuation
N/M 28.9x Lower Multiple NVS
Forward P/E Ratio
Valuation
N/M 15.2x Lower Multiple NVS
Revenue Growth (YoY)
Growth
+0.0% +4.7% Higher Growth NVS
Operating Margin (TTM)
Profitability
0.0% 34.0% Higher Margin NVS
Net Profit Margin
Profitability
0.0% 17.5% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
-233.7% 24.3% Higher ROE NVS
52-Week Range Position
Momentum
11% ($0–$10) 58% ($123–$170) Stronger Trend NVS
Beta / 30D Volatility
Risk Regime
-4.68β · 96% Vol 0.32β · 28% Vol Lower Realized Risk NVS
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 37.0 / 100 (SELL) Higher Composite GNPX
Trailing 12M Revenue (USD)
Operating Scale
N/A $40.5B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 75.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 3.69x PEG · 7.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.26 Book/Sh · -233.7% ROE) $17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVS +23.06 pp
GNPX: -26.77% · NVS: -3.71%
3M Horizon NVS +59.15 pp
GNPX: -63.93% · NVS: -4.78%
6M Horizon GNPX +77.6 pp
GNPX: +76.59% · NVS: -1.01%
1Y Horizon NVS +74.78 pp
GNPX: -56.59% · NVS: +18.19%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNPX vs NVS. Trailing 12-month operating profitability (GNPX 0.0% vs NVS 34.0%) and valuation multiples (GNPX N/M vs NVS 15.2x Forward P/E) are benchmarked directly in Pillar 4 below.

GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M
NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 15.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $285.6B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published

Investor FAQ GNPX vs NVS Key Questions & Quantitative Answers

As of Nov 20, 2026, Novartis AG (NVS) is the stronger overall head-to-head candidate over Genprex, Inc. (GNPX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas NVS carries 37.0/100 (SELL) at $150.47 (15.2x Forward P/E, 34.0% operating margin). Composite vs. Pillar Nuance: While GNPX currently prints a higher short-term Unified Composite Score (42.2/100 HOLD vs. NVS 37.0/100 SELL), NVS captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (34.0% vs. 0.0% operating margin) and revenue trajectory (+4.7% vs. +0.0% YoY). Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile NVS trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 38.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NVS leads the Growth & Scale pillar: GNPX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NVS at +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin). On trailing 12-month operating scale, GNPX generates N/A in USD-normalized revenue versus $40.5B for NVS. In operating R&D and SG&A reinvestment, GNPX deploys N/A (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($16.7B) (0 disclosures) for NVS.

NVS screens cheaper on headline valuation multiples. GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NVS trades at 15.2x Forward P/E, 28.9x Trailing P/E, 3.69x PEG, and 7.1x EV/Revenue (42.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GNPX (-233.7% ROE) versus NVS (24.3% ROE) capital efficiency.

In options market volatility and institutional positioning, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk). By comparison, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.